Published in Drug Metab Dispos on August 14, 1978
Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature (1980) 2.85
Effect of environmental factors on drug metabolism: decreased plasma half-life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides. Clin Pharmacol Ther (1969) 2.75
Response of hepatic microbodies to a hypolipidemic agent, ethyl chlorophenoxyisobutyrate (CPIB). J Cell Biol (1966) 2.29
Impairment of antipyrine clearance in humans by propranolol. Circulation (1978) 2.18
Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion. Arch Gen Psychiatry (1999) 2.03
Drugs as etiologic factors in the Stevens-Johnson syndrome. Am J Med (1968) 1.98
Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol (1969) 1.86
Pharmacokinetics of methotrexate. Clin Pharmacol Ther (1973) 1.55
Structure elucidation of dinucleotides by mass spectrometry. Biochem Biophys Res Commun (1968) 1.40
Relationship between digoxin concentrations in serum and saliva. Clin Pharmacol Ther (1975) 1.38
The effect of spironolactone on antipyrine metabolism in man. Pharmacology (1973) 1.31
Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology (1993) 1.30
Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man. Biochem Pharmacol (1974) 1.28
Absorption of orally given digoxin preparations. JAMA (1972) 1.27
Effects of tobacco and non-tobacco cigarette smoking on endothelium and platelets. Clin Pharmacol Ther (1985) 1.26
The effects of urine pH and plasma protein binding on the renal clearance of disopyramide. Clin Pharmacokinet (1977) 1.25
Decreased rate of creatinine production in patients with hepatic disease: implications for estimation of creatinine clearance. Ther Drug Monit (1983) 1.24
Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res (1974) 1.22
Nafenopin-induced hepatic microbody (peroxisome) proliferation and catalase synthesis in rats and mice. Absence of sex difference in response. J Cell Biol (1974) 1.21
Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther (1976) 1.14
Di-(2-ethylhexyl)phthalate: an industrial plasticizer induces hypolipidemia and enhances hepatic catalase and carnitine acetyltransferase activities in rat and mice. Life Sci (1976) 1.14
Long-term effects of clofibrate (Atromid-S) on serum lipids in man. Circulation (1969) 1.11
Cigarette smoking--induced enhancement of platelet function: lack of prevention by aspirin in men with coronary artery disease. J Lab Clin Med (1985) 1.11
Theophylline bioavailability following chronic dosing of an elixir and two solid dosage forms. J Pharm Sci (1978) 1.09
Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver. Cancer Res (1979) 1.09
Drugs and drug metabolites as environmental contaminants: chlorophenoxyisobutyrate and salicyclic acid in sewage water effluent. Life Sci (1977) 1.07
Clinical complications of corticosteroid therapy. A selected review. Med Clin North Am (1973) 1.06
Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med (1972) 1.04
Effect of in vivo elevation of free fatty acids on protein binding of drugs. Pharmacology (1974) 1.02
Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug. Cancer Res (1979) 1.00
The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin. Pharmacology (1972) 1.00
Correlation between plasma diphenhydramine level and sedative and antihistamine effects. Clin Pharmacol Ther (1978) 0.99
Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet (1978) 0.99
Prescription writing by generic name and drug cost. J Chronic Dis (1967) 0.96
Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse. Arch Int Pharmacodyn Ther (1977) 0.95
Drug interactions with warfarin. Arch Intern Med (1968) 0.95
A comparative study of drug metabolism in the isolated perfused liver and in vivo in rats. Eur J Pharmacol (1970) 0.95
Lack of effect of aspirin on cigarette smoke-induced increase in circulating endothelial cells. Haemostasis (1987) 0.94
Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. J Pharmacol Exp Ther (1975) 0.94
Drug interactions. Pharmacol Physicians (1970) 0.93
Microbodies in experimentally altered cells. VI. Thyroxine displacement from plasma proteins and clofibrate effect. Arch Int Pharmacodyn Ther (1969) 0.93
Effects of model traumatic injury on hepatic drug metabolism in the rat. I. In vivo antipyrine metabolism. Drug Metab Dispos (1984) 0.93
Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest (1975) 0.92
Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans. Cancer Res (1974) 0.92
Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet (1976) 0.92
Daunorubicin metabolism in acute nonlymphocytic leukemia. Clin Pharmacol Ther (1973) 0.88
The effect of spironolactone and canrenone on the digoxin radioimmunoassay. Res Commun Chem Pathol Pharmacol (1974) 0.88
The effect of butoxamine on catecholamine-induced metabolic changes in humans. Clin Pharmacol Ther (1966) 0.87
Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates. Clin Pharmacokinet (1983) 0.87
Absorption and excretion of clindamycin-2-phosphate in children after intramuscular injection. Clin Pharmacol Ther (1972) 0.86
Clofibrate effect on catecholamine-induced metabolic changes in humans. Metabolism (1968) 0.86
The instability of isoniazid and acetylisoniazid in frozen plasma. Res Commun Chem Pathol Pharmacol (1976) 0.86
Plasma levels and excretion of estrogens in urine in chronic lever disease. Gastroenterology (1975) 0.85
Absorption of digoxin from different oral preparations in normal subjects during steady state. Clin Pharmacol Ther (1974) 0.85
Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643. Arch Int Pharmacodyn Ther (1978) 0.85
Association between clinical cardiac status, laboratory parameters, and digoxin usage. Am Heart J (1976) 0.85
Theophylline bioavailability: a comparison of the oral absorption of a theophylline elixir and two combination theophylline tablets to intravenous aminophylline. Am Rev Respir Dis (1977) 0.84
Disposition kinetics of disopyramide in patients with renal insufficiency. Biopharm Drug Dispos (1981) 0.84
Postmarketing surveillance of food additives. Regul Toxicol Pharmacol (1994) 0.84
Bioavailability of aminosalicylic acid and its various salts in humans. 3. Absorption from tablets. J Pharm Sci (1974) 0.83
Effects of selected hypolipidemic drugs on cell ultrastructure. Fed Proc (1971) 0.83
Diphenylhydantoin potency and plasma protein binding. J Pharmacol Exp Ther (1975) 0.83
Interaction of oxygen-carrying resuscitation fluids with morphine. J Lab Clin Med (1984) 0.82
1-methyl-4piperidyl-bis (P-chlorophenoxy) acetate: a new hypolipidemic peroxisome proliferator. Res Commun Chem Pathol Pharmacol (1975) 0.82
Metabolic disposition of antipyrine in patients with lung cancer. Cancer Res (1977) 0.82
Kinetics, salivary excretion of amphetamine isomers, and effect of urinary pH. Clin Pharmacol Ther (1978) 0.81
Quantitation of lidocaine and its deethylated metabolites in plasma and urine by gas chromatography-mass fragmentography. J Chromatogr (1978) 0.81
Pharmacology of hypolipidemic drugs. Introduction. Fed Proc (1971) 0.81
Topical application of lindane cream (Kwell) and antipyrine metabolism. J Invest Dermatol (1980) 0.81
Metabolic responses to plasma concentrations of theophylline. Clin Pharmacol Ther (1979) 0.81
Determination of carbonyl oxygen exchange rates in alpha-ketoacids by gas chromatography-mass spectrometry. Anal Biochem (1982) 0.81
Diphenylhydantoin: correlation between protein binding and albumin concentration. Klin Wochenschr (1975) 0.81
The interaction between halofenate and propranolol. Clin Pharmacol Ther (1976) 0.80
Negligible changes in piglet serum clinical indicators or organ weights due to dietary single-cell long-chain polyunsaturated oils. Food Chem Toxicol (2002) 0.80
Comparison of charcoal and attapulgite as gastrointestinal sequestrants in acute drug ingestions. Clin Toxicol (1971) 0.80
Pharmacokinetic investigations in elderly patients. Clinical and ethical considerations. Clin Pharmacokinet (1990) 0.80
Evidence for the stimulation of dolichol and mannolipid synthesis by glucocorticoids in HeLa cells. Biochem J (1981) 0.80
A two-year crossover therapeutic trial with halofenate and clofibrate. Am J Med Sci (1977) 0.80
Daunorubicin metabolism in acute myelocytic leukemia. Blood (1972) 0.79
Serum digitoxin in uremic patients. Clin Pharmacol Ther (1972) 0.79